HR 1266: Combating Illicit Xylazine Act

HR 1266 in plain English: This bill places xylazine, an animal sedative increasingly found mixed with fentanyl on the street, under Schedule III of the Controlled Substances Act. It sets criminal penalties for illegal manufacturing, distribution, or possession with intent to distribute, while preserving legal veterinary and animal-control uses. It also requires the DEA to track xylazine transactions and report on the drug's illicit use and trafficking.

Stated purpose

This bill aims to combat the illicit use of xylazine — a veterinary sedative increasingly found mixed with street drugs like fentanyl — by placing it under federal controlled substance regulations so its distribution and misuse can be monitored and penalized.

Key points

• Adds xylazine ('tranq') to Schedule III of the Controlled Substances Act, making illicit use federally regulated
• Sets criminal penalties for illegally manufacturing, distributing, or possessing xylazine with intent to distribute
• Exempts veterinarians, pharmacies, and animal-control or wildlife programs from new registration requirements
• Requires DEA to track xylazine transactions and report on prevalence of illicit use and trafficking

Arguments supporters make

• Placing xylazine under federal control gives law enforcement clear legal tools to crack down on traffickers who mix it with fentanyl, making an already deadly drug supply even more dangerous.
• Tracking xylazine transactions through the DEA's reporting system will give public health officials better data to understand and respond to the growing xylazine crisis.
• The bill carefully protects legitimate veterinary and wildlife uses while targeting only illicit trafficking, so farmers, vets, and animal-control workers are not burdened unnecessarily.

Arguments opponents make

• Adding xylazine to Schedule III could create paperwork and registration hurdles for veterinarians and rural animal-care providers, potentially making a widely used animal medication harder to access in a timely way.
• Scheduling xylazine may drive illicit supply toward unregulated substitutes that are equally or more dangerous, without reducing overall harm to drug users.
• Critics may argue that criminal penalties alone do not address the underlying addiction crisis, and that resources would be better spent on treatment and harm-reduction tools like xylazine test strips.

Tradeoffs

Tightening federal control over xylazine may reduce illicit trafficking and improve data collection, but it also adds regulatory burdens on the legitimate veterinary supply chain and may not reach people already using street drugs cut with xylazine.

Current status in Congress: Passed House.

NewsClear — neutral news & congressional tracking · Bill of the Week